Jason Sandoval

Associate

Overview

Jason Sandoval is an associate in the Tax Group in Crowell & Moring’s Washington, D.C. office, where he provides strategic counsel to clients on employee benefits and executive compensation matters. Jason’s experience ensures client compliance with complex laws and regulations, including the Internal Revenue Code, ERISA, HIPAA, COBRA, MHPAEA, No Surprises Act, Public Health Service Act, and the Affordable Care Act.

Before joining Crowell in 2024, Jason served as an attorney-advisor at the IRS, Office of Chief Counsel. His role involved drafting key health and welfare regulations and guidance, including those related to COBRA, fixed indemnity insurance, preventive services under the ACA, and welfare benefit funds. His deep regulatory experience positions him as a valuable asset for clients facing intricate compliance challenges.

Jason earned his Juris Doctor and Master of Laws in tax law from the University of Illinois Chicago School of Law, where he was recognized for academic excellence. His undergraduate background in economics and business administration complements his legal knowledge, offering clients a well-rounded perspective on their financial and regulatory issues. 

In addition to his legal experience, Jason has a keen understanding of assessing and collecting withdrawal liability, having worked as an operations accountant at one of the nation’s largest multiemployer pension funds. Jason is dedicated to providing comprehensive legal support and ensuring that his clients navigate the complexities of tax and employee benefits law with confidence.

Career & Education

|
    • Department of the Treasury
      Attorney-Advisor, IRS, Office of Chief Counsel, 2020–2024
    • Department of the Treasury
      Law Clerk, IRS, Office of Chief Counsel, Health and Welfare Branch and Qualified Plans Branch, 2019
    • Department of the Treasury
      Attorney-Advisor, IRS, Office of Chief Counsel, 2020–2024
    • Department of the Treasury
      Law Clerk, IRS, Office of Chief Counsel, Health and Welfare Branch and Qualified Plans Branch, 2019
    • Illinois State University, 2013
    • University of Illinois Chicago School of Law, J.D., 2020
    • University of Illinois Chicago School of Law, LL.M., 2020
    • Illinois State University, 2013
    • University of Illinois Chicago School of Law, J.D., 2020
    • University of Illinois Chicago School of Law, LL.M., 2020
    • Illinois
    • District of Columbia
    • Illinois
    • District of Columbia
    • Economics Advisory Board, Illinois State University, 2024
    • Illinois State Bar Association
    • Economics Advisory Board, Illinois State University, 2024
    • Illinois State Bar Association

Jason's Insights

Client Alert | 4 min read | 03.25.25

Federal Circuit Affirms Deductibility of Hatch-Waxman Litigation Expenses

In a significant decision for generic drug manufacturers, the Federal Circuit recently affirmed that litigation expenses incurred in defending Hatch-Waxman
patent lawsuits are deductible as ordinary and necessary business expenses under the Internal Revenue Code (IRC). The ruling in Actavis Laboratories FL, Inc.
v. United States, No. 23-1320 (Fed. Cir. Mar. 21, 2025), resolves a key tax dispute, allowing tax deductions for these expenses in the year they are incurred
rather than capitalizing them over time. This outcome provides clarity and potential tax benefits for qualifying businesses navigating the interplay of patent
litigation and FDA drug approvals.
...

Recognition

  • Center for Consumer Information and Insurance Oversight Partnership Award, 2024
  • IRS Commissioner’s Award, 2022

Jason's Insights

Client Alert | 4 min read | 03.25.25

Federal Circuit Affirms Deductibility of Hatch-Waxman Litigation Expenses

In a significant decision for generic drug manufacturers, the Federal Circuit recently affirmed that litigation expenses incurred in defending Hatch-Waxman
patent lawsuits are deductible as ordinary and necessary business expenses under the Internal Revenue Code (IRC). The ruling in Actavis Laboratories FL, Inc.
v. United States, No. 23-1320 (Fed. Cir. Mar. 21, 2025), resolves a key tax dispute, allowing tax deductions for these expenses in the year they are incurred
rather than capitalizing them over time. This outcome provides clarity and potential tax benefits for qualifying businesses navigating the interplay of patent
litigation and FDA drug approvals.
...

Jason's Insights

Client Alert | 4 min read | 03.25.25

Federal Circuit Affirms Deductibility of Hatch-Waxman Litigation Expenses

In a significant decision for generic drug manufacturers, the Federal Circuit recently affirmed that litigation expenses incurred in defending Hatch-Waxman
patent lawsuits are deductible as ordinary and necessary business expenses under the Internal Revenue Code (IRC). The ruling in Actavis Laboratories FL, Inc.
v. United States, No. 23-1320 (Fed. Cir. Mar. 21, 2025), resolves a key tax dispute, allowing tax deductions for these expenses in the year they are incurred
rather than capitalizing them over time. This outcome provides clarity and potential tax benefits for qualifying businesses navigating the interplay of patent
litigation and FDA drug approvals.
...